Evolution of SARS‐CoV‐2 variants of concern over a period of Delta and Omicron cocirculation, among patients hospitalized for COVID‐19 in an Italian reference hospital: Impact on clinical outcomes
Authors: Mondi Annalisa , Mastrorosa Ilaria , Piselli Pierluca , Cimaglia Claudia , Matusali Giulia , Carletti Fabrizio , Giannico Giuseppina , Milozzi Eugenia , Biliotti Elisa , Di Bari Silvia , Chinello Pierangelo , Beccacece Alessia , Faraglia Francesca , Vittozzi Pietro , Mosti Silvia , Tetaj Nardi , Stazi Giulia Valeria , Pinnetti Carmela , Camici Marta , D'Annunzio Alberto , Marani Alessandra , Fabeni Lavinia , Specchiarello Eliana , Gruber Cesare Ernesto Maria , Villanacci Alberta , Minicucci Sabrina , Garbuglia Anna Rosa , Ianniello Stefania , Marchioni Luisa , Taglietti Fabrizio , D'Offizi Gianpiero , Palmieri Fabrizio , Nicastri Emanuele , Maggi Fabrizio , Vaia Francesco , Girardi Enrico , Antinori Andrea 
Published: May 2023

Despite the higher transmissibility of Omicron Variant of Concern (VOC), several reports have suggested lower risk for hospitalization and severe outcomes compared to previous variants of SARS‐CoV‐2. This study, enrolling all COVID‐19 adults admitted to a reference hospital who underwent both the S‐gene‐target‐failure test and VOC identification by Sanger sequencing, aimed to describe the evolving prevalence of Delta and Omicron variants and to compare the main in‐hospital outcomes of severity, during a trimester (December 2021 to March 2022) of VOCs' cocirculation. Factors associated with clinical progression to noninvasive ventilation (NIV)/mechanical ventilation (MV)/death within 10 days and to MV/admission to intensive care unit (ICU)/death within 28 days, were investigated through multivariable logistic regressions. Overall, VOCs were: Delta n = 130/428, Omicron n = 298/428 (sublineages BA.1 n = 275 and BA.2 n = 23). Until mid‐February, Delta predominance shifted to BA.1, which was gradually displaced by BA.2 until mid‐March. Participants with Omicron VOC were more likely to be older, fully vaccinated, with multiple comorbidities and to have a shorter time from symptoms' onset, and less likely to have systemic symptoms and respiratory complications. Although the need of NIV within 10 days and MV within 28 days from hospitalization and the admission to ICU were less frequent for patients with Omicron compared to those with Delta infections, mortality was similar between the two VOCs. In the adjusted analysis, multiple comorbidities and a longer time from symptoms' onset predicted 10‐day clinical progression, while complete vaccination halved the risk. Multimorbidity was the only risk factor associated with 28‐day clinical progression. In our population, in the first trimester of 2022, Omicron rapidly displaced Delta in COVID‐19 hospitalized adults. Clinical profile and presentation differed between the two VOCs and, although Omicron infections showed a less severe clinical picture, no substantial differences for clinical progression were found. This finding suggests that any hospitalization, especially in more vulnerable individuals, may be at risk for severe progression, which is more related to the underlying frailty of patients than to the intrinsic severity of the viral variant.